化学
慢性粒细胞白血病
激酶
酶抑制剂
IC50型
效力
药理学
阿布勒
选择性
蛋白激酶A
白血病
体外
酪氨酸激酶
生物化学
信号转导
生物
免疫学
催化作用
作者
J. Zimmermann,Elisabeth Buchdunger,Helmut Mett,Thomas Meyer,Nicholas Lydon
标识
DOI:10.1016/s0960-894x(96)00601-4
摘要
Abstract Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. Compound 1 shows high potency (IC50 = 38 nM) and selectivity for the Abl tyrosine protein kinase at the in vitro level.
科研通智能强力驱动
Strongly Powered by AbleSci AI